Danirixin (formerly known as GSK-1325756; GSK1325756) is a novel, potent small molecule CXCR2 antagonist being developed as a potential anti-inflammatory drug for COPD.

Burixafor HBr, the hydrobromide salt of Burixafor (TG-0054), is a novel, potent and orally bioavailable antagonist of CXCR4 (CXC chemokine receptor 4) with potential anti-inflammatory activity.

Plerixafor 8HCl (formerly JM-3100; AMD-3100; SDZ-SID-791; JLK-169; SID-791; JM-2987; MOZOBIL), the hydrochloride salt of Plerixafor, is a specific chemokine receptor CXCR4 antagonist used as an immunostimulant to mobilize hematopoietic stem cells in cancer patients into the bloodstream.

UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration.

Reparixin (also known as Repertaxin), is a novel, potent small molecular weight allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.

AMD3465 (AMD-3465) is a novel monomacrocyclic antagonist of CXCR4 with potential anticancer and anti-HIV activity.

AMD3465 hexahydrobromide (AMD-3465; GENZ-644494 6-HBr) is a novel monomacrocyclic antagonist of CXCR4 that has potential anticancer and anti-HIV activity.

AMG-487 (AMG487) is a novel, potent, selective and oral antagonist of chemokine receptor 3 CXCR3 with potential immunomodulatory and antiinflammatory activities.

MSX-130 is novel and potent CXCR4 (Chemokine Receptor 4) inhibitor/antagonist with anticancer activity.

VUF11207 fumarate is a novel, selective and highly potent agonist of CXCR7 (pKi of 8.1) , inducing the recruitment of β-arrestin2 (pEC50 of 8.8) and subsequent internalization (pEC50 of 7.9) of CXCR7.